Abstract 1586P
Background
According to GLOBOCAN's 2024 report breast cancer (BC) is the second leading cause of cancer, posing a significant health challenge in both developed (DE) and developing countries (DC) (Bray F., 2024). Among women, BC is the most commonly diagnosed cancer and the leading cause of cancer deaths, with an estimation of 2.3 million new cases and 666,000 deaths in 2022.
Methods
We performed a critical review of the disparities in BC between DE and DC countries using data from the GLOBOCAN and the North American Association of Central Cancer Registries databases, alongside pertinent literature.
Results
DE countries show substantially higher incidence rates (54.1 vs 30.8 per 100,000), peaking in France, Australia/New Zealand, North America and Northern Europe. Conversely, mortality rates are significantly higher in DC countries (15.3 vs 11.3 per 100,000) (Bray F., 2024). Compared with the risk factors for age-standardized death rate (ASDR) in 1990, smoking and alcohol consumption decreased. In contrast, high plasma glucose and body mass index were ranked as significant contributors to increased ASDR in 2019 (Lv L., 2023). In DE countries, BC incidence increased until 2000, then stabilized and rised again since 2005 (Breen N., 2011). Meanwhile, the mortality rate declined in recent years (Bray F., 2024; Cronin KA., 2022). In contrast, DC countries are witnessing rapid increases in both incidence and mortality rates, driven by socioeconomic transitions, urbanization, obesity, changes in female reproductive patterns and challenges of healthcare systems (Lv L., 2023; Ginsburg O., 2017). Early detection and treatment improve survival rates, but DC countries often face late-stage diagnosis due to limited screening and cancer care (Brand NR., 2019). The WHO’s 2021 Global Initiative aims to lower mortality by 2.5% yearly through enhanced health promotion, early detection and comprehensive management of the disease (WHO., 2023).
Conclusions
BC remains a global challenge with pronounced disparities between DE and DC countries in incidence, mortality and survival. These differences highlight the need for a coordinated global response that addresses risk factors, early detection and ensures access to treatment, regardless of the geographical location.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10
1564P - Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?
Presenter: Allegra Ferrari
Session: Poster session 10
1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital
Presenter: Emmanuel Grolleau
Session: Poster session 10
1567P - Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study
Presenter: Li Xie
Session: Poster session 10
1568P - Challenges in pilot lung cancer screening in Vojvodina, Serbia
Presenter: Jelena Djekic Malbasa
Session: Poster session 10
1569P - Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding study
Presenter: Rahul Agarwal
Session: Poster session 10
1570P - Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
Presenter: Yinghua Ji
Session: Poster session 10
1571P - The reasons that motivate a change of specialties among oncology residents
Presenter: Christophe Ducrocq
Session: Poster session 10
1572P - Factors associated with career choice in oncology among medical students
Presenter: Nicolas Penel
Session: Poster session 10